Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alkermes plc (ALKS) has completed the separation of its oncology business into Mural Oncology plc, an independent, publicly traded company. Mural Oncology will begin regular way trading on the Nasdaq Global Market under the ticker MURA on Nov.
Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program
In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons' stock portfolio.
KCSA appoints Alessandra Nagy as SVP. From PR Week